VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM | CAR-T updates at COSTEM 2021

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, gives an overview of key highlights in the field of chimeric antigen receptor T-cell (CAR-T) therapy being discussed at the 2021 COSTEM meeting. Prof. Nagler discusses the approval of four CAR-T products for various forms of non-Hodgkin lymphoma, and the approval of one CAR-T product for multiple myeloma with another one pending. Prof. Nagler also describes how CAR-T may replace allogeneic transplantation and autologous transplantation and comments on the role of other immunotherapies. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter